Company intelligence / Profile preview
Green Valley
Zhangjiang Science City, Shanghai, Chinagreenvalleypharma.com ↗
- Ownership
- Private
- Employees
- ~1500
- Development stage
- Other
01
Overview
Green Valley developed GV‑971 (sodium oligomannurarate), a first-in-class oral oligosaccharide drug derived from marine brown algae, targeting the brain-gut axis to treat mild-to-moderate Alzheimer’s disease. In a completed Chinese Phase III trial, GV‑971 showed statistically significant cognitive improvement versus placebo with a similar safety profile. It was approved by the NMPA and launched in China as the first new Alzheimer’s drug there in over a decade. A global multicenter Phase III trial for U.S./EU approval has begun enrollment[6][10].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
MMS Holdings Inc. (CRO partner for global clinical trials)[6]
Beyond the preview
Go deeper on Green Valley.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Green Valley.